Citi Initiates Coverage on Genentech (DNA) with a Buy
More News related to DNA
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
- Genentech (DNA) volatility Flat; shares trade above Roche $89 offer
- BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
- JANA Partners 13F Shows New Stakes in Genentech (DNA), Sears (SHLD), Washington Mutual (WM); Adds to Positions in AK Steel (AKS), Focus Media (FMCN), Transocean (RIG); Sells Out of Apple (AAPL), Lehma
- Notable Analyst Rating Changes 8/15: SPWR, PCLN, ADSK Upgraded; JNJ, JWN, DNA Downgraded
More News related to New Coverage
- Market Check: Dow Down 154, Nasdaq Down 50, S&P Down 15
- McCain's Big Surprise - Alaska's Sarah Palin Named VP Running Mate
- McCain Chooses Palin as VP
- Market Check: Dow Down 83, Nasdaq Down 32, S&P Down 9
- Crude Up Over $2, Nearing $118
Citi initiates coverage on Genentech Inc (NYSE: DNA) with a Buy. Price target $91.
Citi analyst says, "Finally a Big Stock Worth Buying - Our upside/downside analysis is favorable as several studies could lead to robust growth. Our rating is based on: (1) 15% (base case) '08-'10E EPS CAGR vs. 12% for biotech group, (2) strong op. margins, (3) little competitive threats, (4) strong news flow in the next 12-24 mos, & (5) potential for 27% '08-'12 EPS CAGR (best case) driven in part by NASBP C-08 trial...We forecast that Avastin could post 17% '08-'12E sales CAGR driven by growth in adjuvant colon, breast and lung cancers."
Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs.
Related Categories
New CoverageStocks Mentioned
+0.30Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
